Regeneron Pharmaceuticals (NASDAQ:REGN) Price Target Raised to $1,100.00

Posted by Brian Himes on Nov 2nd, 2026

Regeneron Pharmaceuticals (NASDAQ:REGN – Get Free Report) had its price objective raised by research analysts at Guggenheim from $1,030.00 to $1,100.00 in a research report issued on Monday, Benzinga reports. The brokerage currently has a “buy” rating on the biopharmaceutical company’s stock. Guggenheim‘s price objective indicates a potential upside of 16.78% from the stock’s previous close.

Several other equities research analysts also recently commented on the company. Benchmark raised Regeneron Pharmaceuticals from a “hold” rating to a “buy” rating and set a $185.00 target price for the company in a report on Tuesday, July 7th. Piper Sandler raised their price target on shares of Regeneron Pharmaceuticals from $854.00 to $865.00 and gave the stock an “overweight” rating in a report on Monday, October 19th. Argus raised shares of Regeneron Pharmaceuticals from a “hold” rating to a “buy” rating and set a $850.00 price target on the stock in a research note on Thursday, October 1st. HSBC increased their price objective on Regeneron Pharmaceuticals from $800.00 to $920.00 and gave the stock a “buy” rating in a report on Thursday, September 10th. Finally, BMO Capital Markets upped their target price on Regeneron Pharmaceuticals from $800.00 to $920.00 and gave the stock an “outperform” rating in a research report on Wednesday, September 9th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-two have given a Buy rating and eight have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $880.45.

View Our Latest Analysis on Regeneron Pharmaceuticals

Regeneron Pharmaceuticals Stock Up 1.5%

REGN stock opened at $941.96 on Monday. The firm has a fifty day moving average price of $793.30 and a two-hundred day moving average price of $738.05. The company has a debt-to-equity ratio of 0.08, a current ratio of 4.06 and a quick ratio of 3.66. Regeneron Pharmaceuticals has a 1-year low of $591.52 and a 1-year high of $935.35. The firm has a market cap of $96.98 billion, a price-to-earnings ratio of 20.87, a PEG ratio of 1.57 and a beta of 0.10.

Regeneron Pharmaceuticals (NASDAQ:REGN – Get Free Report) last issued its quarterly earnings data on Friday, October 30th. The biopharmaceutical company reported $20.07 earnings per share (EPS) for the quarter, topping the consensus estimate of $16.51 by $3.56. The business had revenue of $5.12 billion during the quarter, compared to the consensus estimate of $4.58 billion. Regeneron Pharmaceuticals had a return on equity of 16.01% and a net margin of 28.51%. The business’s revenue was up 36.3% on a year-over-year basis. During the same period in the previous year, the firm posted $11.83 earnings per share. Research analysts predict that Regeneron Pharmaceuticals will post 49.10 EPS for the current year.

Insider Activity at Regeneron Pharmaceuticals

In other Regeneron Pharmaceuticals news, Director Huda Zoghbi sold 800 shares of the company’s stock in a transaction that occurred on Monday, August 10th. The stock was sold at an average price of $800.00, for a total value of $640,000.00. Following the completion of the transaction, the director owned 1,703 shares of the company’s stock, valued at $1,362,400. This represents a 31.96% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Marion Mccourt sold 1,131 shares of the stock in a transaction on Thursday, September 3rd. The shares were sold at an average price of $857.39, for a total transaction of $969,708.09. Following the completion of the transaction, the executive vice president owned 12,003 shares of the company’s stock, valued at approximately $10,291,252.17. This represents a 8.61% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 8,093 shares of company stock valued at $6,506,845 in the last quarter. Company insiders own 6.97% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of REGN. Boston Trust Walden Corp boosted its holdings in shares of Regeneron Pharmaceuticals by 794.1% in the 3rd quarter. Boston Trust Walden Corp now owns 10,667 shares of the biopharmaceutical company’s stock worth $8,088,000 after acquiring an additional 9,474 shares in the last quarter. Chicago Partners Investment Group LLC boosted its position in shares of Regeneron Pharmaceuticals by 29.7% in the 3rd quarter. Chicago Partners Investment Group LLC now owns 2,865 shares of the biopharmaceutical company’s stock worth $2,306,000 after purchasing an additional 656 shares during the last quarter. Covestor Ltd grew its holdings in Regeneron Pharmaceuticals by 31.5% during the third quarter. Covestor Ltd now owns 171 shares of the biopharmaceutical company’s stock valued at $130,000 after purchasing an additional 41 shares during the period. Compass Financial Management LLC lifted its holdings in shares of Regeneron Pharmaceuticals by 4,526.2% during the 3rd quarter. Compass Financial Management LLC now owns 3,007 shares of the biopharmaceutical company’s stock valued at $2,280,000 after purchasing an additional 2,942 shares in the last quarter. Finally, Pzena Investment Management LLC acquired a new position in Regeneron Pharmaceuticals in the 3rd quarter worth $310,000. 83.31% of the stock is currently owned by institutional investors and hedge funds.

More Regeneron Pharmaceuticals News

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

Positive Sentiment: Strong quarterly results: Regeneron reported $5.12 billion in revenue, up 36% year over year and above the $4.58 billion analyst consensus. Adjusted earnings of $20.07 per share also exceeded expectations of $16.51. Regeneron revenue jumps 36% on a bigger Sanofi profit share
Positive Sentiment: Dupixent remains the primary growth engine: Global quarterly Dupixent sales rose 35% to approximately $6.5 billion, reinforcing the strength of Regeneron’s collaboration with Sanofi and supporting expectations for continued earnings growth. Regeneron: 3 Key Takeaways for Long-Term Investors
Positive Sentiment: Pipeline and commercial catalysts: Investors highlighted encouraging Libtayo data in high-risk skin cancer, an expanded BARDA supply agreement for Ebola treatment, and management’s comments about a deep development pipeline. Ongoing share repurchases may also support per-share results. Regeneron Earnings Call Highlights Explosive Growth, Deep Pipeline
Neutral Sentiment: Regeneron declared a quarterly dividend of $0.94 per share, or $3.76 annualized, payable December 3 to shareholders of record November 20. The approximately 0.4% yield is modest but signals continued shareholder returns.
Neutral Sentiment: Citigroup has forecast further appreciation, while the stock’s breakout to a two-year and 52-week high reflects strong investor momentum. However, the recent rally raises questions about how much future growth is already reflected in the valuation. Regeneron Bolts Higher on Dupixent Dominance
Negative Sentiment: At roughly $928 per share, Regeneron has risen substantially and may face profit-taking or valuation pressure if future results do not maintain the current pace of growth. Regeneron Stock Looks At A Discount To Earnings

About Regeneron Pharmaceuticals

(Get Free Report)

Regeneron Pharmaceuticals, Inc is a biotechnology company that discovers, develops and commercializes medicines for serious medical conditions. The company uses genetic and antibody-based research technologies to develop treatments in areas including eye diseases, allergic and inflammatory conditions, cancer, cardiovascular disease, infectious diseases and rare disorders.

Its marketed products include Eylea and Eylea HD for retinal diseases, Dupixent for several inflammatory and allergic conditions, Libtayo for certain cancers, Praluent for cardiovascular disease, Kevzara for rheumatoid arthritis, and other medicines such as Inmazeb, Evkeeza, Veopoz and Arcalyst.